amgen glp 1 drug Once Monthly Weight Loss Maritide Shows High Discontinuation Rates in Phase II Trial GLP-1 Agonists Market Report 2025-2033,

RGC was reported in 17 (19%) of the GLP-1RA users as compared to 5 (5%) of the non-users, with an associated adjusted odds ratio (OR) increased by almost 6-fold (5.8 with 95% confidence interval [95% CI]: 1.719.3, P = 0.004)

His past medical history is positive for obesity and hypertension

10.3389/fphar.2022.855779 33 IshikawaM.TakasekiS.YoshitomiT.CoveyD

Older adults may be more sensitive to appetite suppression and weight loss, requiring more conservative dosing or closer monitoring

After 68 weeks, participants receiving a 2.4 mg weekly semaglutide dose experienced a 49% reduction in C-reactive protein (CRP), while those on a 1 mg weekly dose saw a 42% reduction compared to placebo